



3R MATRIX


Right Sector (RS)



Right Quality (RQ)



Right Valuation (RV)



+ Positive

= Neutral

- Negative

What has changed in 3R MATRIX

	Old		New
RS	Grey	↔	Grey
RQ	Grey	↑	Green
RV	Green	↔	Green


Company details

Market cap:	Rs. 58,338 cr
52-week high/low:	Rs. 1765/973
NSE volume: (No of shares)	7.3 lakh
BSE code:	500271
NSE code:	MFSL
Free float: (No of shares)	26.3 cr

Shareholding (%)

Promoters	1.7
FII	44.8
DII	47.3
Others	6.2

Price chart



Source: NSE India, Mirae Asset Sharekhan Research

Price performance

(%)	1m	3m	6m	12m
Absolute	6.2%	7.9%	12.2%	44.4%
Relative to Sensex	5.1%	2.3%	6.9%	39.1%

Source: Mirae Asset Sharekhan Research, Bloomberg

Max Financial Services Ltd

Healthy Q2; structural story intact

Insurance	Sharekhan code: MFSL		
Reco/View: Buy	↔	CMP: Rs. 1,690	Price Target: Rs. 1,910 ↑

Summary

- Q2FY26 numbers were operationally strong, led by robust margins and healthy premium growth
- APE grew 15% y-o-y in H1FY26 which enabled market share gains, structural improvement in profitability was seen, renegotiation of distributor commissions, cost efficiencies, product repricing to mitigate VNB margin stress.
- Lower GST on premiums would pave way for sustainable growth, while other possible regulatory changes to be positive.
- We roll over our valuations and accordingly we revise our PT to Rs. 1,910 on the stock with a Buy rating.

Good show in Q2: Q2FY26 and H1FY26 financials were operationally strong, marked by healthy growth, margin expansion, and improving business quality, with VNB rising 25% y-o-y to Rs. 640 crore and VNB margin improving to 25.5% in Q2FY26, on a favourable product mix shift toward higher-margin segments. Retail protection and health APE alone grew 36% y-o-y in H1FY26, underlining a structural improvement in profitability. The loss of GST input tax credit created a 60-bps headwind to VNB margin in H1FY26, but this is being actively mitigated through distributor commission renegotiation, cost optimisation, product repricing, and operational efficiencies, allowing the company to maintain its FY26 VNB margin guidance at 24-25%.

Growth momentum stayed robust, with gross premium income up 18% y-o-y to Rs.15490 crore in H1FY26, renewal premium also up 18% y-o-y to Rs.9530 crore, and APE growth of 15% y-o-y, enabling market share expansion to 10.1% in H1FY26 from 9.3% a year earlier. Distribution performance remained a key strength, led by the proprietary channel with 22% y-o-y growth. Persistency metrics showed meaningful enhancement in longer-term cohorts, with 25th-month persistency improving 500 bps y-o-y to 76% and 61st-month persistency improving 200 bps y-o-y to 54%, reflecting better underwriting quality and sustainability of earnings. As per latest data for October 2025, the new business premium (YTD) for Max life increased by 17.2% YoY and was higher than industry growth of 8.3% YoY.

Regulatory tailwinds: Lowering of GST on premiums for individual life and health insurance products was rationalised to zero from 18% earlier while input tax credit(ITC) was also withdrawn. However, overall, premiums in general have reduced, other levers such as commission negotiations, operating cost optimization and re-balancing of product portfolio will cover up for the absence ITC. Lower premiums pave way for sustainable growth in insurance business as insurance penetration still remains low at 3.8% for FY24.

The government's proposed move to table the Insurance Laws (Amendment) Bill, 2025 during the sixth session of the 18th Lok Sabha marks a significant step toward a unified, future-ready reform agenda that could shape the evolution of India's still underpenetrated insurance market over the next decade. Industry participants are optimistic that the Bill will secure final clearance, paving the way for stronger growth, increased capital participation, and greater innovation across the sector.

Proposed rise in FDI limits from 74% to 100% could bring substantial capital in the sector, reduce net owned fund requirements from Rs. 5000 crore to Rs. 500 crore will aid new age insurers, composite licensing will enable single insurer to provide more differentiated offerings and also integrated or bundled solutions as per customer requirements, flexibility for individual agents to sell policies from multiple insurers will enhance scope of policy distribution. On overall basis all these positive developments ensure bright outlook for insurance sector in medium-to long term and this shall positively reflect on Max Financials' performance as well.

Reverse merger time-line key: If Insurance Bill gets the Parliament nod in the Winter or Budget Session, there will be greater visibility on the schedule for the reverse merger of Max Life with Max Financial Services. This reverse merger, which is aimed at eliminating a holding company discount and listing the insurance business directly, could be a key catalyst for the stock.

Our Call

Valuation and Outlook: The management reiterated its FY26 APE growth guidance of 15-17% and medium-term RoEV guidance of 18-19%, and maintained its VNB margin guidance in 24-25%, supported by the ongoing mix shift toward higher-margin products and cost discipline. The GST-related margin headwind appearing manageable within its broader long-term growth and profitability trajectory. Hence, we expect healthy levels in persistency, continued market share gain, and resilient overall performance. We roll over our valuations and value the stock at ~2.2x Average Embedded Value for FY27-FY28E, thus accordingly we revise our PT to Rs1910 on the stock with a Buy rating.

Key Risks

Slow APE growth, any pressure on VNB margins and any adverse regulatory policies/guidelines may impact financial performance.

Valuation

Particulars	FY24	FY25	FY26E	FY27E	Rs cr FY28E
APE (Rs cr)	7,433	8,770	10,086	11,649	13,396
VNB (Rs cr)	1,973	2,107	2,423	2,811	3,289
VNB Margin (%)	26.5	24.0	24.0	24.1	24.5
EV (Rs cr)	19,494	25,192	29,475	34,338	40,347
ROEV (%)	20.2	17.7	18.2	18.3	18.4
P/EV (x)	3.7	2.9	2.4	2.1	1.8
P/VNB (x)	36.5	34.2	29.7	25.6	21.9

Source: Company; Mirae Asset Sharekhan estimates

Outlook and Valuation

■ Sector Outlook – Large opportunity, but competition, regulatory risks higher

Insurance penetration is still low in India as compared to international benchmarks. Factors such as a large protection gap and expanding per capita income are key long-term growth drivers for the sector. India has a high protection gap; and credit protection products are still at an early stage and has the potential to grow multi-fold as penetration of retail loans improves in the country. Hence, we believe the insurance sector has a huge growth potential in India. Against this backdrop, we believe that strong players with the right mix of products, services, and distribution is likely to gain disproportionately from the opportunity. However, there is a high risk of regulatory changes/ competition, which can impact profitability.

■ Company Outlook – Eyeing balanced outcomes

Max Financial is building a strong franchise with a multi-channel distribution network built upon a balanced product mix. Over the medium term, management has indicated a balanced mix of business with non-PAR, ULIP and protection. We believe cost management, re-balancing of the product mix, and further diversification of distribution channels are key levers for improvement in profitability and growth. Reverse merger remains a key catalyst besides industry-leading performance.

■ Valuation – Maintain Buy with revised PT of Rs. 1910

The management reiterated its FY26 APE growth guidance of 15–17% and medium-term RoEV guidance of 18–19%, and maintained its VNB margin guidance in 24–25%, supported by the ongoing mix shift toward higher-margin products and cost discipline. The GST-related margin headwind appearing manageable within its broader long-term growth and profitability trajectory. Hence, we expect healthy levels in persistency, continued market share gain, and resilient overall performance. We roll over our valuations and value the stock at ~2.2x Average Embedded Value for FY27-FY28E, thus accordingly we revise our PT to Rs1910 on the stock with a Buy rating.

About company

Max Financial Services Limited (MFSL) is part of India's leading business conglomerate – Max Group. Focused on life insurance, MSFL currently owns majority stake in life Insurance business, which is the sole operating subsidiary of MFSL. Axis Max Life Insurance Company Limited is a Joint Venture between Max Financial Services Limited and Axis Bank Limited. It has built its operations over two decades, offers comprehensive long-term savings, protection, and retirement solutions through its high-quality agency and multi-channel distribution partners.

Investment theme

The company has gained critical mass and enjoys strong operating parameters in the industry. We believe the company's well-diversified product mix and strong distribution channel augur well and will help sustain healthy business growth.

Key Risks

- ♦ Slow APE growth, lower VNB margins and any adverse regulatory policies/guidelines may affect its profitability.

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	MS&AD Insurance Group Holdings Inc	21.86
2	HDFC Asset Management Co Ltd	9.13
3	Nippon Life India Asset Management	5.70
4	Nippon Life India Trustee Ltd	5.64
5	ICICI Prudential Asset Management	3.33
6	Vanguard Group Inc/The	3.14
7	Kotak Mahindra Asset Management Co	2.99
8	DSP Finance Pvt Ltd	2.95
9	KOTAK MAHINDRA TRUSTEE CO LTD	2.93
10	Capital Group Cos Inc/The	2.81

Source: Bloomberg

Mirae Asset Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Mirae Asset Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/ weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Mirae Asset Sharekhan Research

DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation, and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to change without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, and outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply to information/documents focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. Mirae Asset Sharekhan will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable, and Mirae Asset Sharekhan has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on a reasonable basis, Mirae Asset Sharekhan, its subsidiaries and associated companies, their directors, and employees ("Mirae Asset Sharekhan and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent Mirae Asset Sharekhan and its affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance, and the value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Mirae Asset Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Mirae Asset Sharekhan and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restrictions.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in the securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of Mirae Asset Sharekhan. The analyst and Mirae Asset Sharekhan further certifies that either he or his relatives or Mirae Asset Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and Mirae Asset Sharekhan encourage independence in research report/ material preparation and strive to minimize conflict in the preparation of the research report. The analyst and Mirae Asset Sharekhan do not have any material conflict of interest or have not served as officers, directors or employees or engaged in market-making activity of the company. The analyst and Mirae Asset Sharekhan have not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd, or its associates, or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from a third party in the past twelve months in connection with the research report.

Either Mirae Asset Sharekhan or its affiliates or its directors or employees/representatives/clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. Mirae Asset Sharekhan may from time to time solicit from, or perform investment banking or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall Mirae Asset Sharekhan, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Sharekhan Ltd and its affiliates undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgment before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Mirae Asset Sharekhan has been ranked as India's No.1 Retail Broker by Asiamoney Brokers Poll 2023. For more details, visit bit.ly/AsiamoneyPoll

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registered Office: 1st Floor, Tower No. 3, Equinox Business Park, LBS Marg, Off BKC, Kurla (West), Mumbai 400 070, Maharashtra, India. Tel: 022-67502000.

Correspondence/Administrative Office Address - Gigaplex IT Park, Unit No 1001, 10th floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai - 400708. Tel: 022 61169000 / 61150000.

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited - (AMFI-registered Mutual Fund Distributor), Research Analyst Regn No.: INH000006183. CIN: U99999MH1995PLC087498.

SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD) / MCX - Commodity: INZ000171337; BSE - 748, NSE - 10733, MCX - 56125, DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669 (date of initial registration: 03/07/2004, and valid till 02/07/2026); IRDAI Registered Corporate Agent (Composite) License No. CA0950, valid till June 13, 2027.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-4657 3809; email id: complianceofficer@sharekhan.com

For any complaints/ grievances, email us at igc@sharekhan.com, or you may even call the Customer Service desk on 022-41523200/ 022-61151111.